<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617704</url>
  </required_header>
  <id_info>
    <org_study_id>GBF003</org_study_id>
    <nct_id>NCT04617704</nct_id>
  </id_info>
  <brief_title>BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma</brief_title>
  <official_title>Exploratory Study to Evaluate Efficacy and Safety of GC012F Injection in Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gracell Biotechnology Shanghai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open label, multi-center prospective study to explory the safety and&#xD;
      efficacy of GC012F CAR-T cells in patient diagnosed with high-risk chromosomal abnormalities&#xD;
      BCMA+ multiple myeloma(MM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main aim of this study is to determin the safety and efficacy of GC012F in cytogenetic&#xD;
      high-risk MM. GC012F is an autologus dual chimeric antigen receptor T-cell(CAR-T) therapy&#xD;
      that targets B-cell maturation antigen(BCMA) and CD19. This study comprises of a screening&#xD;
      phase(less than or equal to 28 days prior to apheresis) followed by apheresis(will occur upon&#xD;
      enroiiment); Treatment Phase including autologus stem cell transplant on Day-1 followed by&#xD;
      infusion of GC012F on Day0 and then post-infusion assessments from Day1 to Day 84; and a&#xD;
      Post-treatment Phase(Day 85 and up to end of the study). Efficacy will be explored to&#xD;
      assessed and safety will be closely monitored during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events after GC012F injection</measure>
    <time_frame>Minimum 2 years after GC012F infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of MRD negative patients after GC012F infusion</measure>
    <time_frame>Minimum 2 years after GC012F infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR(PR, VGPR, CR and sCR) of patients after GC012F treatment</measure>
    <time_frame>Minimum 2 years after GC012F infusion(Day0)</time_frame>
    <description>percent of subjects who achieving PR or better after GC012F infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival after GC012F treatment</measure>
    <time_frame>Minimum 2 years after GC012F infusion(Day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response of subjects after GC012F treatment</measure>
    <time_frame>Minimum 2 years after GC012F infusion(Day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survivalof subjects after GC012F treatment</measure>
    <time_frame>Minimum 2 years after GC012F infusion(Day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines in serum after GC012F infusion</measure>
    <time_frame>Minimum 24 weeks after GC012F infusion(Day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of lymphocytes in blood after GC012F infusion</measure>
    <time_frame>Minimum 2 years after GC012F infusion(Day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-GC012F antibodies in blood after GC012F infusion</measure>
    <time_frame>Minimum 2 years after GC012F infusion(Day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell counts of GC012F in blood and bone marrow(if available) after GC012F infusion</measure>
    <time_frame>Minimum 2 years after GC012F infusion(Day0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Copies of GC012F in blood and bone marrow(if available) after GC012F infusion</measure>
    <time_frame>Minimum 2 years after GC012F infusion(Day0)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Experimental:GC012F treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCMA+ cytogenetic high-risk multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)*10^5/kg cells will be administered at Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC012F injection</intervention_name>
    <description>GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.</description>
    <arm_group_label>Experimental:GC012F treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of active MM as defined by any of following: a) serum M protein more than or&#xD;
             equal to 10g/dL; b) urine M protein more than or equal to 200mg/24 h; c) involved&#xD;
             serum free light chain more than or equal to 100mg/dL with abnormal serum kappa lambda&#xD;
             ratio;&#xD;
&#xD;
          2. Patients with clear BCMA expression(percent of BCMA positive plasma cells more than or&#xD;
             equal to 20%) detected by flow cytometry;&#xD;
&#xD;
          3. High-risk chromosomal abnormal defined as presence of del17p, and/or t(4;14) and/or&#xD;
             t(14;16);&#xD;
&#xD;
          4. Estimated life expectancy more than or equal to 3 months;&#xD;
&#xD;
          5. Absolute neutrophil count more than or equal to 1*10^9/L;&#xD;
&#xD;
          6. Platelet count more than or equal to 25*10^9/L;&#xD;
&#xD;
          7. Absolute lymphocyte count more than or equal to 1*10^8/L;&#xD;
&#xD;
          8. Liver, kidney and cardiopulmonary functions meet the following requirements: a) Total&#xD;
             bilirubin less than or equal to 2*ULN(except for Gilbert Syndrome); ALT and AST less&#xD;
             than or equal to 2.5*ULN, maintenance of kidney function not depend on dialysis;&#xD;
             c)Corrected serum calcium less than or equal to 12.5 mg/dL or free ion calcium less&#xD;
             than or equal to 6.5mg/dL(1.6mmol/L);&#xD;
&#xD;
          9. Sufficient venous access for leukapheresis collection and no other contraindications&#xD;
             to leukapheresis;&#xD;
&#xD;
         10. Subjects and sexual partner with fertility are willing to use effective and reliable&#xD;
             method of contraception for at least 1 year after CAR-T infusion;&#xD;
&#xD;
         11. subjects must have signed writtern informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Accompanied by other unctrolled maligancies. Two exceptions to this criteria: Recepted&#xD;
             radical therapy carcinoma without activity within 3 years before screening; fully&#xD;
             treated skin non-melanoma;&#xD;
&#xD;
          2. Any situations not benefit for subjects to accept or tolerated to planned therapy or&#xD;
             understand informed consent; or any situation in which investigators believe that&#xD;
             participation in this study is not in the subject's best intreat(eg., harm to health),&#xD;
             or any situation that may prevent, limit or confuse the assessment;&#xD;
&#xD;
          3. Convulsion or stoke within past 6 months;&#xD;
&#xD;
          4. Any instability or systemic disease within 6 months prior to screening, including but&#xD;
             not limited to congestive heart failure(New York heart association classification ≥&#xD;
             III)， unstable angina, cerebrovascular accident, or transient cerebral ischemic,&#xD;
             myocardial infarction, LEVF&lt;50%(assessed by an echocardiogram or multi-door circuit&#xD;
             scan);&#xD;
&#xD;
          5. Patients have central nervous system(CNS) metastases or CNS involvement(including&#xD;
             cranial neuropathies or mass lesions and leptomeningeal disease);&#xD;
&#xD;
          6. Subjects with positive HBsAg or HBcAb positive and peripheal blood HBV-DNA titer is&#xD;
             higher than the lower limit of detection of the research institution; HCV antibody&#xD;
             positive; HIV antibody positive; syphilis primary screening antibody positive;&#xD;
&#xD;
          7. Presence or suspicious of fungi, bacteria, viruses or other infections that are&#xD;
             uncontrollable or requiring intravenous treatment;&#xD;
&#xD;
          8. Activity of autoimmune disease (such as crohn's disease, rheumatoid arthritis,&#xD;
             systemic lupus erythematosus), orhistory of autoimmune disease within the last 3&#xD;
             years;&#xD;
&#xD;
          9. Clinical evidence of dementia or changes of mental state;&#xD;
&#xD;
         10. Exist of pulmonary fibrosis;&#xD;
&#xD;
         11. Allergy subjects or history of severe hypersensitivity;&#xD;
&#xD;
         12. Oxgen inhalation requirement to maintain adequate oxygen saturation;&#xD;
&#xD;
         13. Surgery (except for local anesthesia surgery) plan 2 weeks before apheresis, during or&#xD;
             2 weeks after CAR-T infusion;&#xD;
&#xD;
         14. Patients who are accounted to be not appropriate for this investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weijun Fu</last_name>
    <phone>+8613816052522</phone>
    <phone_ext>+8613816052522</phone_ext>
    <email>fuweijun2010@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Weijun Fu</investigator_full_name>
    <investigator_title>Director of Hematology Department</investigator_title>
  </responsible_party>
  <keyword>high-risk</keyword>
  <keyword>Fast</keyword>
  <keyword>Chimeric Antigen Receptor T</keyword>
  <keyword>BCMA</keyword>
  <keyword>CD19</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

